Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Hansoh Pharmaceutical Group has entered into a lucrative global license agreement with Merck Sharp & Dohme LLC, granting exclusive rights to develop, manufacture, and commercialize its investigational GLP-1 receptor agonist, HS-10535. This deal includes an upfront payment of $112 million, potential milestone payments reaching up to $1.9 billion, and royalties, showcasing Hansoh’s strategic move to leverage its technology platforms for financial growth. The agreement also provides Hansoh opportunities to co-promote or solely commercialize the product in mainland China, Hong Kong, and Macau.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.